Untangling the effects of N-glycosylation on cognitive decline
Description: Our recent studies show that altered N-glycosylation of proteins in cerebrospinal fluid (CSF) and blood in nondemented individuals can predict future cognitive decline and Alzheimer´s disease (AD) dementia. We propose to elucidate the link between N-glycosylation and cognitive decline in this 5-year project. The overarching aim is to develop glycan and glycopeptide biomarkers for early detection and subgrouping of individuals at risk of developing dementia and decipher how glycans are related to disease mechanisms. Mechanistic studies will be performed by altering glycosyltransferase activities in neurons and studying the effects on morphology, subcellular localization and levels of pathogenic proteins by cutting-edge super-resolution microscopy and protein analysis. Time-course glycosylation alterations will be studied in animal models. Glycoproteomics will be performed to identify glycopeptide alterations in brain, cerebrospinal fluid and blood from AD and other dementias. The utility of glycopeptides as predictive biomarkers for AD or other dementias will be assessed by statistical analysis of associations with other biomarkers and, especially, with cognitive data in longitudinal cohorts. Mass spectrometric methods and well-plate assays will be implemented clinically. The findings from this project could revolutionize diagnostics in primary and secondary care by providing glycoprotein biomarkers for predicting future cognitive decline earlier than current biomarkers.
Funder: Vetenskapsrådet
Amount: SEK 5,400,000
Funding type: research
Funder scheme: Project grant
Start date: 2026-01-01
End date: 2029-12-31
Investigator: Sophia Schedin Weiss (lead)
Institution: Karolinska Institutet
Subfield: Molecular Biology
Domain: Life Sciences
Funded outputs count: 0
Funder award ID: 2025-03082
OpenAlex ID: G7963292836
